申请人:Grue-Sørensen Gunnar
公开号:US20140303150A1
公开(公告)日:2014-10-09
The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
本发明涉及一般式I的化合物,其中R是杂环芳基,可选择由R7取代; 或R是杂环烷基或杂环烯基,可选择由R8取代; 或R是X,其中X是—NR11R12;以及其药学上可接受的盐、水合物或溶剂化物,用于治疗,单独或与一个或多个其他药学活性化合物联合使用,预防、治疗或改善对嗜中性粒细胞氧化爆发刺激、对角质细胞IL-8释放刺激或对坏死诱导反应的疾病或病情的响应。